Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SERENA-4
2020-002276-12Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Feb 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing camizestrant plus palbociclib with anastrozole plus palbociclib (2 arms). Primary endpoint: Progression-free survival. Started Feb 2021; status: active.
02
Drugs
camizestrantpalbociclibanastrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2020-002276-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002276-12.